• Tuesday, Sep 29, 2020
  • Last Update : 10:06 am

US developing coronavirus strain for human 'challenge' trials

  • Published at 10:04 am August 15th, 2020
New York coronavirus
File photo: People walk on a street near Herald Square, in New York City on June 25, 2020 AFP

NIAID said it would probably reach a decision toward the end of 2020, when the late-stage clinical trials that are underway start reporting their results

US scientists are developing a strain of the coronavirus that could be used to deliberately infect volunteers in so-called "challenge studies," a government agency said Friday.

The work is preliminary and the government is continuing to prioritize randomized clinical trials of vaccine candidates, the National Institute for Allergies and Infectious Diseases (NIAID) said.

Several of these have entered their final stages, including the vaccines developed by Moderna, Pfizer and AstraZeneca.

But NIAID has nonetheless "begun efforts to manufacture a strain that could be used to develop a human challenge model, if needed," it said in a statement.

In normal clinical trials, volunteers receive either a medicine or a placebo and their health is then followed over the course of months of years.

Scientists look for how well the vaccine or treatment worked when the person was naturally exposed to the pathogen.

A quicker way to test whether a drug works is by deliberately infecting volunteers, as has been done in the past for influenza, malaria, typhoid, dengue fever, and cholera.

In the US, advocacy groups like 1DaySooner support challenge studies for Covid-19, but the subject is controversial because of how serious the disease can be and because its effects aren't fully understood.

NIAID said it would probably reach a decision toward the end of 2020, when the late-stage clinical trials that are underway start reporting their results.

This would help it determine whether challenge studies are needed, safe and ethical, it added.

David Diemert, the director of George Washington University's vaccine trial research unit who is overseeing a trial of Moderna's vaccine in the US capital, told AFP he did not think challenge trials were appropriate for Covid-19.

"I think they're a critical tool, but only under the right circumstances," he said.

Diemert is himself leading a challenge trial into a hookworm vaccine.

But he said that for Covid-19, "we don't have a very clear understanding of who is at risk of developing severe disease and we have no treatment that is guaranteed to cure someone if they do develop severe disease."

There's also enough widespread community transmission in the US -- the worst hit country in the world with 5.3 million confirmed cases -- to mean challenge trials are not necessary, he added.

50
50
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail